The Ministry of Health has just issued the Circular No. 36/2015/TT-BYT dated October 29, 2015 of the Ministry of health on amending a number of Articles of the Circular No. 40/2014/TT-BYT dated November 17, 2014 on issuing and guiding the implementation of the List of modern medicines covered by health insurance.
Within that, the most important supplementation is on medicines on List of modern medicines covered by health insurance. Accordingly, any medicine that contains multiple active ingredients, one of which is subject to certain conditions or prescriptions for payment, then such medicine shall be paid according to the active ingredient subject to conditions/prescriptions for payment. Any medicine that contains multiple active ingredients, two or more of which is subject to certain conditions for payment, all the limits of conditions and prescriptions for payment shall be concurrently applied.
Besides, the Circular also emphasizes that the health insurance shall pay 100% charges for a patient with cancer is treated with Pegylated liposomal Doxorubicin (injectable form); Erlotinib (oral form); Gefitinib (oral form), Sorafenib (oral form) at a medical facility before the Circular No. 40/2014/TT-BYT dated November 17, 2014 comes into effect and is discharged from the hospital after 01/01/2015. Such medicines are used during the whole course of therapy (from the time the diagnosis is made to the time the treatment finishes) and after receiving treatment at a medical facility, the patient moves to another medical facility and such medicines are prescribed according to the same course of therapy, then the health insurance shall fully cover the treatment charges within his/her right.